Verdiva Bio initiates Phase I study of obesity drug
Verdiva Bio has dosed the first patient in a Phase I SAD study evaluating VRB-103, a once-weekly selective oral amylin analog, as a treatment for overweight and obesity. The Phase I randomised, double-blind, placebo-controlled study will assess the safety and tolerability of VRB-103, in healthy patients with… Read More
